ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2015
Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2388 health care providers.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Acupuncture for nausea and vomiting induced by highly emetogenic chemotherapy: a systematic review and meta-analysis.Frontiers in neurology · 2025Pooled it
- Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation.Drug design, development and therapy · 2018Trial
- A cost-utility analysis of risk model-guided versus physician's choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Trial
- Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2015Trial
- Neurokinin-1 receptor antagonists in the current management of chemotherapy-induced nausea and vomiting.Frontiers of medicine · 2025Review
- GDF15 Analogues Acting as GFRAL Ligands.ChemMedChem · 2025Review
- Nausea and vomiting in an evolving anticancer treatment landscape: long-delayed and emetogenic antibody-drug conjugates.Future oncology (London, England) · 2025Review
- Central mechanisms of emesis: A role for GDF15.Neurogastroenterology and motility · 2025Review
- Serious Gaming for Chemotherapy-Induced Nausea and Vomiting in Older Adults With Cancer: Protocol for a Randomized Clinical Trial.JMIR research protocols · 2024Article
- Feasibility and User Experience of Digital Patient Monitoring for Real-World Patients With Lung or Breast Cancer.The oncologist · 2024Article
- Creation of a Peptide Antagonist of the GFRAL-RET Receptor Complex for the Treatment of GDF15-Induced Malaise.Journal of medicinal chemistry · 2023Article
- Screening study of anti-emetics to improve GDF15-induced malaise and anorexia: Implications for emesis control.Physiology & behavior · 2023Article
- Article
- Comparison of netupitant/palonosetron with 5-hydroxytryptamine-3 receptor antagonist in preventing of chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation.Frontiers in oncology · 2023Article
- Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation.Clinical hematology international · 2022Review
- Article
- Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE).Oncology and therapy · 2022Article
- Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice.Current cancer drug targets · 2022Review
- Unplanned emergency department visits and hospital admissions of older adults under treatment for cancer in the ambulatory/community setting.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- Granisetron Extended-Release Subcutaneous Injection versus Palonosetron Infusion for CINV Prevention: Cost Comparison of Unscheduled Hydration.American health & drug benefits · 2021Article
Corrections and comments
- Commented on by
- Commented on byResponse.2015
Authors and funding
3 authors.
Funding
Abstract
purposeBecause as many as 30% of cancer patients who receive chemotherapy of moderate or high emetogenic potential suffer from chemotherapy-induced nausea and vomiting (CINV), we undertook a multinational survey to identify health care providers’ perceived knowledge gaps, barriers,and educational interests relevant to CINV.
methodsAn Internet-based survey was developed and was electronically disseminated to members of Medscape, an international Internet-based continuing medical education provider.
resultsA total of 2388 health care providers responded to the survey. Although breakthrough nausea and vomiting was the most common CINV-related issue they managed in the preceding year, managing delayed nausea was the most problematic in that time period. Thirty-two percent of health care providers delayed or discontinued a patient’s chemotherapy because of CINV. Cost of antiemetics, patients’ poor adherence to antiemetic regimens, and health care providers’ underestimation of risk for CINV were all barriers to effective management. Health care providers expressed a wide range of educational interests, including managing breakthrough CINV, keeping up with novel antiemetic agents, and learning about emerging approaches for CINV prevention/management.
conclusionsThis survey of health care providers uncovered key barriers and educational needs relevant to the management of CINV. The findings from this survey can be used to develop educational initiatives focused on improving the care of cancer patients at risk for or suffering from CINV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.